Suchergebnisse - Portal für Medizinische Datenmodelle (MDM-Portal)

Suchergebnisse filtern
Datenmodelle auswählen

Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

536 Suchergebnisse.

Eligibility Diabetes NCT01507389

- 17.09.21 - 1 Formular, 2 Itemgruppen, 13 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function; ODM derived from: https://clinicaltrials.gov/show/NCT01507389

Eligibility Diabetes Mellitus NCT00355537

- 17.09.21 - 1 Formular, 2 Itemgruppen, 13 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Testosterone Replacement in Diabetes With Vascular Disease (Version 2); ODM derived from: https://clinicaltrials.gov/show/NCT00355537

Eligibility Diabetes Mellitus NCT01075997

- 02.09.21 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

The Impact of a Video Cell Phone Reminder System on Glycemic Control in Patients With Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT01075997

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Diabetes mellitus sub-cohort

- 28.06.21 - 1 Formular, 11 Itemgruppen, 26 Datenelemente, 1 Sprache

Itemgruppen: Diabetes Mellitus details, Hemoglobin A1c (HbA1c ) in blood, C-peptide in blood, Glucose in blood, C-peptide-to-Glucose Ratio (CGR) in blood, Insulin level in blood, Cortisol level in blood, Insulin treatment before SARS-CoV-2 detection (Baseline), Change of insulin scheme at the time of SARS-CoV-2 detection (Baseline), Oral antidiabetic treatment before SARS-CoV-2 detection (Baseline), Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for the Diabetes mellitus sub-cohort. If a text field can't be filled out, note 'ND'.

Measurement Instrument Database for the Social Science (MIDSS) - Appraisal of Diabetes Scale (ADS)

- 13.09.20 - 1 Formular, 1 Itemgruppe, 7 Datenelemente, 1 Sprache

Itemgruppe: DCAI-R (7/88)

Carey, M. P., Jorgensen, R. S., Weinstock, R. S., Sprafkin, R. P., Lantinga, L. J., Carnrike, C. L. M., Jr., Baker, M. T., & Meisler, A. W. (1991). Appraisal of Diabetes Scale (ADS). Measurement Instrument Database for the Social Science. Retrieved 13.09.20, from www.midss.ie Key references: Carey, M. P., Jorgensen, R. S., Weinstock, R. S., Sprafkin, R. P., Lantinga, L. J., Carnrike, C. L. M., Jr., Baker, M. T., & Meisler, A. W. (1991). Reliability and validity of the appraisal of diabetes scale. Journal of Behavioral Medicine, 14, 43-51. Garratt, A.M., L. Schmidt, and R. Fitzpatrick (2002) Patient-assessed health outcome measures for diabetes: a structured review. Diabetic Med., 19, 1-11. Trief, P.M., W. Grant, K. Elbert, and R.S. Weinstock (1998) Family environment, glycemic control, and the psychosocial adaptation of adults with diabetes. Diabetes Care 21, 241-245. Trief, P.M., C. Aquilino, K. Paradies, and R.S. Weinstock (1999) Impact of the work environment on glycemic control and adaptation to diabetes. Diabetes Care 22, 569-574. Primary use / Purpose: The Appraisal of Diabetes Scale (ADS) is a 7-item self-report scale assessing the individual's appraisal of his or her diabetes. Respondents rate each statement on a 5 point Likert scale. The scale's author state that the ADS can be incisive as a relatively quick (5 minute) screening tool to examine a patient’s adjustment to diabetes or risk for noncompliance with a care regimen. The test is easily administered (written or oral form) and is simple to score and interpret. The smaller the total score, the more positive the appraisal strategy. Thus, lower scores are better. Background: The Appraisal of Diabetes Scale (ADS) was developed and tested with 200 male subjects, two thirds of whom were taking insulin treatment with an mean age of 58 years. All subjects provided blood for routine monitoring of HbA1c, half the subjects completed the ADS as well as five other self-report measures, and the other half completed the ADS on three time points over the course of one week. No significant difference was observed between ADS scores for insulin-dependent and non-insulin-dependent subjects. The ADS has been used in studies parsing the effects of family environment (Trief et al. 1998) and work environment (Trief et al. 1999) on glycemic control and psychosocial adaptation in adults with diabetes. Psychometrics: The psychometric properties of the ADS are examined in Carey et al. (1991). Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.274 Scoring the ADS is easy: 1. Reverse score items # 2 and 6. ADS2R = 5 - ADS2 ADS6R = 5 - ADS6 2. Then sum all items, using the reversed scored items 2 and 6. Total score = ADS1 + ADSR2 + ADS3 + ADS4 + ADS5 + ADSR6 + ADS7 There is no manual. Interpretation is straightforward: The smaller the total score, the more positive the appraisal strategy. Thus, lower scores are better.

Eligibility Loss of Control of Diabetes NCT01889706

- 05.07.20 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Metformin Therapy in Type 1 Diabetes Mellitus.; ODM derived from: https://clinicaltrials.gov/show/NCT01889706

Eligibility Islet Transplantation in Diabetes Mellitus Type 1, NCT01817959

- 28.04.20 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation; ODM derived from: https://clinicaltrials.gov/show/NCT01817959

Eligibility Diabetes NCT02351323

- 19.11.19 - 1 Formular, 2 Itemgruppen, 21 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Novel Type 2 Diabetes Mellitus Preventive Therapies; ODM derived from: https://clinicaltrials.gov/show/NCT02351323

Eligibility Diabetes NCT02219269

- 19.11.19 - 1 Formular, 2 Itemgruppen, 19 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

A Complex Contraception Registry; ODM derived from: https://clinicaltrials.gov/show/NCT02219269

Eligibility Diabetes NCT02161588

- 18.11.19 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT02161588

Eligibility Diabetes NCT02146079

- 18.11.19 - 1 Formular, 2 Itemgruppen, 14 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT02146079

Eligibility Diabetes NCT01900834

- 16.11.19 - 1 Formular, 2 Itemgruppen, 15 Datenelemente, 1 Sprache

Itemgruppen: Inclusion Criteria, Exclusion Criteria

Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period; ODM derived from: https://clinicaltrials.gov/show/NCT01900834

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.